{"id":745499,"date":"2017-09-08T07:00:00","date_gmt":"2017-09-08T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/"},"modified":"2025-11-07T01:26:18","modified_gmt":"2025-11-07T06:26:18","slug":"updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/","title":{"rendered":"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the presentation of data from all three cohorts of the<br \/>\n      registrational, phase 2 KEYNOTE-059 trial investigating the use of<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1 therapy,<br \/>\n      in patients with advanced gastric or gastroesophageal junction (GEJ)<br \/>\n      adenocarcinoma, including new data in treatment-na\u00efve patients. Overall,<br \/>\n      results showed antitumor activity and durability of response with<br \/>\n      KEYTRUDA across multiple lines of therapy, with higher response rates<br \/>\n      observed in PD-L1-positive (CPS \u22651) patients:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In heavily pre-treated patients, KEYTRUDA monotherapy (Cohort 1)<br \/>\n        showed an overall response rate (ORR) of 12 percent (95% CI, 8-17) in<br \/>\n        all patients and 16 percent (95% CI, 11-23) in patients with PD-L1<br \/>\n        positive tumors.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In treatment-na\u00efve patients, KEYTRUDA in combination with chemotherapy<br \/>\n        (Cohort 2) showed an ORR of 60 percent (95% CI, 39-79) in all patients<br \/>\n        and 69 percent (95% CI, 41-89) in patients with PD-L1 positive tumors.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In treatment-na\u00efve patients with PD-L1 positive tumors, KEYTRUDA<br \/>\n        monotherapy (Cohort 3) showed an ORR of 26 percent (95% CI, 12-45).\n      <\/li>\n<\/ul>\n<p>\n      Results are being presented at the European Society for Medical Oncology<br \/>\n      (ESMO) 2017 Congress in Madrid, Spain, in an oral presentation on<br \/>\n      Friday, Sept. 8 from 3:03-3:15 p.m. CEST (Location: Barcelona<br \/>\n      Auditorium) (Abstract #LBA28_PR).\n    <\/p>\n<p>\n      \u201cOutcomes can vary significantly among patients with gastric or GEJ<br \/>\n      cancer \u2013 across stages of disease and based on a variety of biological<br \/>\n      and molecular makeups of tumors,\u201d said Charles S. Fuchs, M.D., MPH, lead<br \/>\n      investigator and director of Yale Cancer Center. \u201cKEYNOTE-059 was<br \/>\n      designed to provide important insight across various treatment settings,<br \/>\n      simultaneously, and these results show encouraging activity with<br \/>\n      pembrolizumab in both previously treated and treatment-na\u00efve patients,<br \/>\n      particularly in those with high levels of PD-L1 expression.\u201d\n    <\/p>\n<p>\n      \u201cThese findings across lines of therapy in gastric and GEJ cancers<br \/>\n      continue to support the potential for KEYTRUDA, and PD-L1 as a<br \/>\n      biomarker, in patients with this advanced stage disease,\u201d said Dr. Roger<br \/>\n      Dansey, senior vice president and therapeutic area head, oncology<br \/>\n      late-stage development, Merck Research Laboratories. \u201cWe are encouraged<br \/>\n      by the responses observed in heavily pre-treated patients and look<br \/>\n      forward to continued analysis of data in treatment-na\u00efve patients.\u201d\n    <\/p>\n<p>\n      Merck\u2019s broad clinical program encompasses multiple gastrointestinal<br \/>\n      disorders \u2013 such as gastroesophageal cancer and microsatellite<br \/>\n      instability-high (MSI-H) colorectal cancer \u2013 and includes four<br \/>\n      gastric\/GEJ cancer registration-enabling studies and numerous other<br \/>\n      gastrointestinal cancer studies currently underway.\n    <\/p>\n<p>\n      <b>Data from KEYNOTE-059 Study Cohorts (Abstract #LBA28_PR)<\/b>\n    <\/p>\n<p>\n      Results presented from KEYNOTE-059 were based on an analysis of<br \/>\n      efficacy, safety and PD-L1 expression from 315 patients across the<br \/>\n      study\u2019s three cohorts. Patients were considered PD-L1 positive if they<br \/>\n      had a PD-L1 combined positive score of one or more (CPS \u22651). Findings<br \/>\n      showed:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <span class=\"bwuline\">Cohort 1: KEYTRUDA (pembrolizumab) as<br \/>\n        monotherapy in patients whose disease progressed on or after two or<br \/>\n        more prior lines of therapy (n=259)<\/span>. Forty-eight percent of<br \/>\n        these patients had received three or more lines of prior therapy. The<br \/>\n        efficacy analysis in all patients, with or without PD-L1 expression,<br \/>\n        showed an ORR of 12 percent (95% CI, 8-17), with complete responses<br \/>\n        (CR) in three percent (95% CI, 1-6) and partial responses (PR) in nine<br \/>\n        percent (95% CI, 6-13) of patients. In patients whose tumors expressed<br \/>\n        PD-L1 (n=148), the ORR was 16 percent (95% CI, 11-23), with CR in<br \/>\n        three percent (95% CI, 1-8) and PR in 13 percent (95% CI, 8-19) of<br \/>\n        patients. In PD-L1 negative patients (n=109), the ORR was six percent<br \/>\n        (95% CI, 3-13), with CR in three percent (95% CI, 1-8) and PR in four<br \/>\n        percent (95% CI, 1-9) of patients. Median duration of follow-up was<br \/>\n        5.6 months (range: 0.5-24.7). In all patients, 42 percent (n=95)<br \/>\n        experienced a reduction in target lesion size. Median duration of<br \/>\n        response was 14.2 months (range: 2.4-19.4+).<\/p>\n<p>In all<br \/>\n        patients, median progression-free survival (PFS) was two months (95%<br \/>\n        CI, 2.0-2.1), with a six-month PFS rate of 14.6 percent; the median<br \/>\n        overall survival (OS) was 5.5 months (95% CI, 4.2-6.5), with a<br \/>\n        six-month OS rate of 45.7 percent. In patients whose tumors expressed<br \/>\n        PD-L1, the median PFS was 2.1 months (95% CI, 2.0-2.1), with a<br \/>\n        six-month PFS rate of 18.2 percent; the median OS in these patients<br \/>\n        was 5.8 months (95% CI, 4.4-7.8), with a six-month OS rate of 48.4<br \/>\n        percent. In PD-L1 negative patients, the median PFS was two months<br \/>\n        (95% CI, 1.9-2.0), with a six-month PFS rate of 9.9 percent; the<br \/>\n        median OS was 4.6 months (95% CI, 3.2-6.5), with a six-month OS rate<br \/>\n        of 42.9 percent.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <span class=\"bwuline\">Cohort 2: KEYTRUDA (pembrolizumab) in<br \/>\n        combination with chemotherapy in treatment-na\u00efve patients (n=25). <\/span>The<br \/>\n        efficacy analysis in all patients showed an ORR of 60 percent (95% CI,<br \/>\n        39-79), with CR in four percent (95% CI, 0-20) and PR in 56 percent<br \/>\n        (95% CI, 35-76) of patients. In patients whose tumors expressed PD-L1<br \/>\n        (n=16), the ORR was 69 percent (95% CI, 41-89), with no complete<br \/>\n        responses (95% CI, 0-22) and PR in 69 percent (95% CI, 41-89) of<br \/>\n        patients. In PD-L1 negative patients (n=8), the ORR was 38 percent<br \/>\n        (95% CI, 9-76), with CR in 13 percent (95% CI, 0-53) and PR in 25<br \/>\n        percent (95% CI, 3-65) of patients. Median duration of follow-up was<br \/>\n        13.8 months (range: 1.8-24.1). Across all patients, 96 percent (n=24)<br \/>\n        experienced a reduction in target lesion size. Median duration of<br \/>\n        response was 4.6 months (range: 2.6-20.3+). In all patients, median<br \/>\n        PFS was 6.6 months (95% CI, 5.9-10.6), with a six-month PFS rate of<br \/>\n        68.0 percent; the median OS was 13.8 months (95% CI, 8.6-not reached),<br \/>\n        with a six-month OS rate of 76.0 percent.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <span class=\"bwuline\">Cohort 3: KEYTRUDA as monotherapy in<br \/>\n        treatment-na\u00efve patients whose tumors expressed PD-L1 (n=31)<\/span>.<br \/>\n        The efficacy analysis showed an ORR of 26 percent (95% CI, 12-45),<br \/>\n        with CR in seven percent (95% CI, 1-21) and PR in 19 percent (95% CI,<br \/>\n        8-38) of patients. Median duration of follow-up was 17.5 months<br \/>\n        (range: 1.7-20.7). Seventy-seven percent of patients (n=24)<br \/>\n        experienced a reduction in target lesion size. The median duration of<br \/>\n        response was 9.6 months (range: 2.1-17.8+). The median PFS was 3.3<br \/>\n        months (95% CI, 2.0-6.0), with a six-month PFS rate of 34.9 percent;<br \/>\n        the median OS was 20.7 months (95% CI, 9.2-20.7), with a six-month OS<br \/>\n        rate of 72.9 percent.\n      <\/li>\n<\/ul>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies. In Cohorts 1, 2 and 3, Grade 3-5<br \/>\n      treatment-related adverse events (TRAEs) occurred in 46 (18%), 19 (76%),<br \/>\n      and 7 (23%) patients, respectively. In Cohort 1, Grade 3-5 TRAEs were<br \/>\n      anemia (3%), fatigue (2%), and dehydration (1%); TRAEs led to<br \/>\n      discontinuation in seven patients (3%) and death in two patients (1%).<br \/>\n      In Cohort 2, Grade 3\/4 TRAEs were neutropenia (24%), stomatitis (20%),<br \/>\n      anemia (8%), decreased platelet count (8%), decreased appetite (8%), and<br \/>\n      fatigue (8%). TRAEs in Cohort 2 led to discontinuation in three patients<br \/>\n      (12%); there were no treatment-related deaths. In Cohort 3, Grade 3-5<br \/>\n      TRAEs occurred in seven patients (23%); there was one treatment-related<br \/>\n      death (3%) and no discontinuations due to TRAEs.\n    <\/p>\n<p>\n      In Cohorts 1, 2 and 3, Grade 3 or higher immune-mediated adverse events<br \/>\n      occurred in 13, four, and three patients, respectively. In Cohort 1,<br \/>\n      Grade 3 immune-mediated adverse events were colitis (n=3), pneumonitis<br \/>\n      (n=2), thyroiditis (n=1), and hypothyroidism (n=1); there were no Grade<br \/>\n      4-5 immune-mediated adverse events. In Cohort 2, Grade 3 immune-mediated<br \/>\n      adverse events were palmar-plantar erythrodysesthesia (n=2), nephrotic<br \/>\n      syndrome (n=1), rash (n=1), and maculopapular rash (n=1); there were no<br \/>\n      Grade 4-5 immune-mediated adverse events. In Cohort 3, Grade 3<br \/>\n      immune-mediated adverse events were colitis (n=1) and rash (n=1); there<br \/>\n      was one Grade 5 adverse event (pneumonitis).\n    <\/p>\n<p>\n      <b>About KEYNOTE-059<\/b>\n    <\/p>\n<p>\n      KEYNOTE-059 is a registrational, phase 2 non-randomized, multi-cohort<br \/>\n      study (Cohorts 1, 2 and 3) investigating KEYTRUDA (pembrolizumab) in<br \/>\n      patients with advanced gastric or GEJ adenocarcinoma. Patients in Cohort<br \/>\n      1 received KEYTRUDA monotherapy after two or more prior lines of<br \/>\n      therapy. Patients in Cohort 2 had received no prior therapy and received<br \/>\n      KEYTRUDA in combination with cisplatin (80 mg\/m<sup>2<\/sup> Q3W) and<br \/>\n      5-fluorouracil (800 mg\/m<sup>2<\/sup> Q3W) or capecitabine (in Japan<br \/>\n      only, 1000 mg\/m<sup>2<\/sup> BID Q3W) as a first-line therapy. Patients<br \/>\n      in Cohort 3, which only enrolled patients whose tumors were positive for<br \/>\n      PD-L1, received KEYTRUDA monotherapy as a first-line therapy. In all<br \/>\n      cohorts, KEYTRUDA was given at 200 mg every three weeks for up to 24<br \/>\n      months. The primary endpoints are safety (all cohorts) and ORR using<br \/>\n      Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Key<br \/>\n      secondary endpoints are ORR and duration of response by RECIST v1.1,<br \/>\n      PFS, and OS. Data from Cohorts 1 and 2 were further assessed based on<br \/>\n      PD-L1 expression. Tumors were considered to have positive PD-L1<br \/>\n      expression if the combined positive score (CPS) \u2013 as examined by tumor<br \/>\n      and immune cells \u2013 was equal to or greater than one.\n    <\/p>\n<p>\n      <b>About Gastric Cancer<\/b>\n    <\/p>\n<p>\n      Gastric cancer, also called stomach cancer, is a type of cancer that<br \/>\n      begins in the stomach and tends to develop slowly over many years. Most<br \/>\n      gastric cancers are adenocarcinomas, which develop from the cells of the<br \/>\n      innermost lining (mucosa) of the stomach. Risk factors for gastric<br \/>\n      cancer include gender, age, ethnicity, geography and infection with <i>Helicobacter<br \/>\n      pylori<\/i>. Worldwide, gastric cancer is the fifth most common type of<br \/>\n      cancer and the third leading cause of cancer death. Each year there are<br \/>\n      approximately 952,000 newly diagnosed cases of gastric cancer resulting<br \/>\n      in approximately 723,000 deaths worldwide.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 550 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA (pembrolizumab) is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA<br \/>\n      (pembrolizumab) is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>\u00a0<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.3%) thyroiditis. Monitor patients for changes in thyroid<br \/>\n      function (at the start of treatment, periodically during treatment, and<br \/>\n      as indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA (pembrolizumab)<br \/>\n      and administer corticosteroids. For signs and symptoms of SJS or TEN,<br \/>\n      withhold KEYTRUDA and refer the patient for specialized care for<br \/>\n      assessment and treatment. If SJS or TEN is confirmed, permanently<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682\n    <\/p>\n<p>\n      patients with metastatic NSCLC. The most common adverse event resulting<br \/>\n      in permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%).The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs<br \/>\n      50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%),<br \/>\n      vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%),<br \/>\n      decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs<br \/>\n      18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA (pembrolizumab) as compared to carbo\/pem alone for any<br \/>\n      specified adverse reaction.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients<br \/>\n      with cHL, and treatment was interrupted due to adverse reactions in 26%<br \/>\n      of patients. Fifteen percent (15%) of patients had an adverse reaction<br \/>\n      requiring systemic corticosteroid therapy. Serious adverse reactions<br \/>\n      occurred in 16% of patients. The most frequent serious adverse reactions<br \/>\n      (\u22651%) included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and<br \/>\n      herpes zoster. Two patients died from causes other than disease<br \/>\n      progression; one from GVHD after subsequent allogeneic HSCT and one from<br \/>\n      septic shock. The most common adverse reactions (occurring in \u226520% of<br \/>\n      patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in\u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA (pembrolizumab) was pneumonitis (1.9%).<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 20% of<br \/>\n      patients; the most common (\u22651%) were urinary tract infection (1.5%),<br \/>\n      diarrhea (1.5%), and colitis (1.1%). The most common adverse reactions<br \/>\n      (20%) in patients who received KEYTRUDA vs those who received<br \/>\n      chemotherapy were fatigue (38% vs 56%), musculoskeletal pain (32% vs<br \/>\n      27%), pruritus (23% vs 6%), decreased appetite (21% vs 21%), nausea (21%<br \/>\n      vs 29%), and rash (20% vs 13%). Serious adverse reactions occurred in<br \/>\n      39% of KEYTRUDA-treated patients, the most frequent (\u22652%) of which were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. Efficacy for<br \/>\n      pediatric patients was extrapolated from the results in the adult cHL<br \/>\n      population. In a study of 40 pediatric patients with advanced melanoma,<br \/>\n      PD-L1\u2013positive advanced, relapsed, or refractory solid tumors or<br \/>\n      lymphoma, patients were treated with KEYTRUDA for a median of 43 days<br \/>\n      (range 1-414 days), with 24 patients (60%) receiving treatment for 42<br \/>\n      days or more. The safety profile in pediatric patients was similar to<br \/>\n      that seen in adults treated with KEYTRUDA. Toxicities that occurred at a<br \/>\n      higher rate (\u226515% difference) in these patients when compared to adults<br \/>\n      under 65 years of age were fatigue (45%), vomiting (38%), abdominal pain<br \/>\n      (28%), hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=43e79bee721b16a9344d13b4d40d5aea\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=e4653ea40a56ca250a4082418bd69d9d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=5187f41680ce6a1409a34b34117f4da3\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=c95d576d3ec0db101bed951697b54f28\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=06a668982b336593bcce02e80e25af0c\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=98dddbd637021115f878e8e4d998a4c9\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=b3b6781ce5c5f685de327cc80836158e\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=d0fc9e9a768db4200a5dffc1e5b59041\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n      ###\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=ee6d4c51d21aca177055eca085ca121b\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>\u00a0and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51680661&amp;newsitemid=20170908005412&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=f52cc36fe1bbbe5e4699ce4e973879e5\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170908005412r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck <br \/> <span>Media\u00a0Contacts:<\/span> <br \/>Pamela        Eisele, 267-305-3558<br \/>or<br \/>Ann Bush, 908-740-6677<br \/>or<br \/> <span>Investor        Contacts:<\/span> <br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Amy Klug,        908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, including new data in treatment-na\u00efve patients. Overall, results showed antitumor activity and durability of response with KEYTRUDA across multiple lines of therapy, with higher response rates observed in PD-L1-positive (CPS \u22651) patients: In heavily pre-treated patients, KEYTRUDA monotherapy (Cohort 1) showed an overall response rate (ORR) of 12 percent (95% CI, 8-17) in all patients and 16 percent (95% CI, 11-23) in patients with PD-L1 positive tumors. In treatment-na\u00efve patients, KEYTRUDA in combination with chemotherapy (Cohort 2) showed an ORR of 60 percent (95% CI, 39-79) in all patients and 69 percent (95% CI, 41-89) in patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745499","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, including new data in treatment-na\u00efve patients. Overall, results showed antitumor activity and durability of response with KEYTRUDA across multiple lines of therapy, with higher response rates observed in PD-L1-positive (CPS \u22651) patients: In heavily pre-treated patients, KEYTRUDA monotherapy (Cohort 1) showed an overall response rate (ORR) of 12 percent (95% CI, 8-17) in all patients and 16 percent (95% CI, 11-23) in patients with PD-L1 positive tumors. In treatment-na\u00efve patients, KEYTRUDA in combination with chemotherapy (Cohort 2) showed an ORR of 60 percent (95% CI, 39-79) in all patients and 69 percent (95% CI, 41-89) in patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"24 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\\\/\",\"name\":\"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-09-08T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/","og_locale":"en_US","og_type":"article","og_title":"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, including new data in treatment-na\u00efve patients. Overall, results showed antitumor activity and durability of response with KEYTRUDA across multiple lines of therapy, with higher response rates observed in PD-L1-positive (CPS \u22651) patients: In heavily pre-treated patients, KEYTRUDA monotherapy (Cohort 1) showed an overall response rate (ORR) of 12 percent (95% CI, 8-17) in all patients and 16 percent (95% CI, 11-23) in patients with PD-L1 positive tumors. In treatment-na\u00efve patients, KEYTRUDA in combination with chemotherapy (Cohort 2) showed an ORR of 60 percent (95% CI, 39-79) in all patients and 69 percent (95% CI, 41-89) in patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"24 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/","name":"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-09-08T07:00:00+00:00","dateModified":"2025-11-07T06:26:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-data-for-mercks-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-across-treatment-settings-to-be-presented-at-esmo-2017-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Updated Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"668b1d5a-c3f0-4637-8854-b5692d41ce56","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745499\/revisions"}],"predecessor-version":[{"id":3674856,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745499\/revisions\/3674856"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745499"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}